The state of cancer care in Russia: lymphomas. Hodgkin's lymphoma (c81). Prevalence and survival of patients (clinical and population study) (lecture). Part 1

In recent decades, significant progress has been made in the treatment of patients with systemic hematolymphoid malignancies. The quality of primary registration of patients with Hodgkin's lymphoma (HL) has reached a high level. In accordance with the international classification of diseases (ICD-10), two large groups of tumors are classified as hematolymphoid malignancies: HL - C81 and non-Hodgkin's lymphomas (NHL) - C82-85. In the first part of our study, the main purpose is to study the patterns of morbidity, mortality, and the accounting quality of patients with Hodgkin's disease (C81). We have the opportunity to consider not only generalized data, but also a detailed description of the dynamics of the structure, taking into account the fourth sign of the ICD-10. Purpose. The purpose of our study is to study the prevalence (morbidity and mortality), the quality of primary registration of patient with Hodgkin’s disease (C81), the impact of coronavirus pandemic, modern possibilities of early diagnosis and treatment of patients, which was facilitated by the organization of the first Population Cancer Registry (PCR in Russia in 1993. The PCR operates according to international standards. In 2019, coverage at the federal district level totaled almost 14 million people (more than the population of Belarus, Latvia and Estonia combined). The database (DB) of PCR in the North-West Federal District of Russian Federation (NWFD RF) currently totals more than 1.6 million observations. Sufficient DB allows analyzing the efficiency of patient’s treatment with the fourth ICD-10 sign. Materials and Methods. Data from the International Agency for Research on Cancer (IARC), reference books of the P. A. Hertsen National Medical Research Radiological Centre of the Ministry of Health and the N.N. Petrov National Medicine Research Center of Oncology, DB PCR of St. Petersburg and NWFD of the Russian Federation are the material of the study. Data processing was performed using M3 Exce1 2013-2016 and STAT15T1CA 6.1, including standard methods of oncology statistics. Results. The study showed a 13-year decrease in the incidence of the Hodgkin’s lymphoma (C81) in Russia by 5,5% and mortality by 45,1%.